Hottub News

Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC

1 report from 1 outlet in 1 language · first reported · updated · JSON

Science & technologyInnoventnon-small-cell lung carcinoma

Reports

  1. Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLCrdrnews.com · en ·

More in Science & technology

  1. FTC probes AI labs over potential risks to consumers50 outlets
  2. 217-year-old mystery solved in six hours: AI deciphered Napoleon's letter42 outlets
  3. Meet the air traffic controller who flies himself to work47 outlets
  4. OpenAI notifies Australia about new attack by an agent76 outlets
  5. OpenAI fires three staff for mishandling 'sensitive' info37 outlets
  6. iPhone 18 Pro Max bug kills AT&T connection, leaving users needing a new phone32 outlets